A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer

European Urology

Volumn 65, Issue 3, 2014, Pages 516-520

  Wiechno, Paweł ^a   Somer, Bradley G ^b   Mellado, Begoña ^c   Chłosta, Piotr L ^d   Cervera Grau, José Manuel ^e   Castellano, Daniel ^f   Reuter, Christoph ^g   Stöckle, Michael ^h   Kamradt, Jörn ^h   Pikiel, Joanna ⁱ   Durán, Ignacio ^j   Wedel, Steffen ^k   Callies, Sophie ^l   André, Valérie ^l   Hurt, Karla ^l   Brown, Jacqueline ^l   Lahn, Michael ^l   Heinrich, Bernhard ^m  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b ACORN Research LLC   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d JAGIELLONIAN UNIVERSITY   (Poland)

^e Hospital Clinic Benidorm   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h SAARLAND UNIVERSITY   (Germany)

ⁱ Wojewódzkie Cancer Centre   (Poland)

^j HM Hospitales Centro Integral Oncológico Hospital de Madrid Clara Campal   (Spain)

^k GOETHE UNIVERSITY   (Germany)

^l ELI LILLY AND COMPANY   (United States)

^m Haematological Oncological Practice Brudler Heinrich Bangerter   (Germany)

more..

Author keywords

Antisense oligonucleotide; Castration resistant prostate cancer; Docetaxel; LY2181308; Survivin

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CASTRATION-RESISTANT PROSTATE CANCER; DOCETAXEL; LY2181308; SURVIVIN;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; HUMANS; MALE; OLIGONUCLEOTIDES; PREDNISONE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS;

EID: 84895060456     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.10.039     Document Type: Article

References (10)

1. A. Jemal, M.M. Center, C. DeSantis, and E.M. Ward Global patterns of cancer incidence and mortality rates and trends Cancer Epidemiol Biomarkers Prev 19 2010 1893 1907
2. D.P. Petrylak, C.M. Tangen, and M.H. Hussain et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520 (Pubitemid 39315318)
3. I.F. Tannock, R. de Wit, W.R. Berry TAX 327 Investigators Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
4. D.R. Berthold, C.N. Sternberg, and I.F. Tannock Management of advanced prostate cancer after first-line chemotherapy J Clin Oncol 23 2005 8247 8252 (Pubitemid 46211562)
5. S. Fukuda, and L.M. Pelus Survivin, a cancer target with an emerging role in normal adult tissues Mol Cancer Ther 5 2006 1087 1098 (Pubitemid 43881300)
6. R.A. Carrasco, N.B. Stamm, E. Marcusson, G. Sandusky, P. Iversen, and B.K. Patel Antisense inhibition of survivin expression as a cancer therapeutic Mol Cancer Ther 10 2011 221 232
7. D.C. Talbot, M. Ranson, and J. Davies et al. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study Clin Cancer Res 16 2010 6150 6158
8. R.C. Serlin, T.R. Mendoza, Y. Nakamura, K.R. Edwards, and C.S. Cleeland When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function Pain 61 1995 277 284
9. H. Kishi, M. Igawa, N. Kikuno, T. Yoshino, S. Urakami, and H. Shiina Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis J Urol 171 2004 1855 1860 (Pubitemid 38501022)
10. D.J. Brennan, E. Rexhepaj, and S.L. O'Brien et al. Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer Clin Cancer Res 14 2008 2681 2689